Protocol Ledger

NCT07227350 · Phase II · RECRUITING

L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)

Interventional Phase II clinical trial protocol NCT07227350 sponsored by Philogen S.p.A in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-01 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07227350
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07227350
Protocol FieldVerified Registry Value
NCT IdentifierNCT07227350
Consolidated Lead SponsorPhilogen S.p.A
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2026-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI